<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) AND (c) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(AMENDMENT NO. 1)
SCHEIN PHARMACEUTICAL, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of Class of Securities)
806416 10 3
(CUSIP Number)
JULY 6, 2000
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
Page 1 of 4 Pages
<PAGE> 2
================================================================================
CUSIP NO. 806416 10 3 13G PAGE 2 OF 4 PAGES
================================================================================
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BAYER CORPORATION
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
N/A (b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
INDIANA
--------------------------------------------------------------------------------
| 5 SOLE VOTING POWER
|
NUMBER OF | -0-
SHARES |
BENEFICIALLY |
OWNED BY |
EACH |
REPORTING |
PERSON |------------------------------------------------------------
WITH | 6 SHARED VOTING POWER
|
| -0-
|
|------------------------------------------------------------
| 7 SOLE DISPOSITIVE POWER
|
| -0-
|
|------------------------------------------------------------
| 8 SHARED DISPOSITIVE POWER
|
| -0-
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.0%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
================================================================================
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE> 3
This Amendment No. 1 supplements and amends the Statement on Schedule
13G filed on February 12, 1999 by Bayer Corporation (the "Schedule 13G").
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
The response to Item 5 of the Schedule 13G is hereby amended to read in
its entirety as follows:
On July 6, 2000, the reporting person ceased to beneficially
own any shares of common stock of Schein Pharmaceutical, Inc.
<PAGE> 4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: August 1, 2000 BAYER CORPORATION
By: /s/ JON R. WYNE
----------------------
Jon R. Wyne
Senior Vice President and Treasurer
